Top

Published in:

01-12-2014 | Update in Gnathic Pathology. Guest Editors: Angela Chi, DMD and John Wright, DDS

Molecular and Genetic Aspects of Odontogenic Lesions

Authors: Elizabeth A. Bilodeau, Joanne L. Prasad, Faizan Alawi, Raja R. Seethala

Published in: Head and Neck Pathology | Issue 4/2014

Abstract

In this article we outline the molecular findings of select odontogenic tumors. In each section, we briefly review selected the clinicoradiographic, histologic, immunologic features, focusing on the molecular findings and their applications in practice. The understanding of molecular pathobiology at various other organ sites has developed quite rapidly in recent years, however much remains unknown about the genetic profile of odontogenic tumors. Improved understanding of mutations in odontogenic tumors may clarify classification schema and elucidate targets for novel therapies. Molecular testing will no doubt improve our understanding of odontogenic tumor pathogenesis and will likely be, someday, an important component of routine clinical practice and its role will only increase in the coming years.

Barnes L, Eveson J, Reichart P, Sidransky D. Pathology and genetics of head and neck tumours. Lyon: IARC Press; 2005.

Takeda Y. Ameloblastic fibroma and related lesions: current pathologic concept. Oral Oncol. 1999;35(6):535–40.PubMedCrossRef

Muller S, Parker DC, Kapadia SB, Budnick SD, Barnes EL. Ameloblastic fibrosarcoma of the jaws. A clinicopathologic and DNA analysis of five cases and review of the literature with discussion of its relationship to ameloblastic fibroma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1995;79(4):469–77.PubMedCrossRef

Neville BW, Allen CM, Bouquot JE. Odontogenic cysts and tumors. Oral and maxillofacial pathology. 3rd ed. St. Louis: Saunders Elsevier; 2009. p. 678–740.

Galvao CF, Gomes CC, Diniz MG, Vargas PA, de Paula AM, Mosqueda-Taylor A, et al. Loss of heterozygosity (LOH) in tumour suppressor genes in benign and malignant mixed odontogenic tumours. J Oral Pathol Med. 2012;41(5):389–93. doi:10.1111/j.1600-0714.2011.01115.x.PubMedCrossRef

Williams MD, Hanna EY, El-Naggar AK. Anaplastic ameloblastic fibrosarcoma arising from recurrent ameloblastic fibroma: restricted molecular abnormalities of certain genes to the malignant transformation. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007;104(1):72–5. doi:10.1016/j.tripleo.2006.07.013.PubMedCrossRef

Brown NA, Rolland D, McHugh JB, Weigelin HC, Zhao L, Lim MS, et al. Activating FGFR2-RAS-BRAF mutations in ameloblastoma. Clin Cancer Res. 2014. doi:10.1158/1078-0432.CCR-14-1069.

Sarkar A, Hochedlinger K. The sox family of transcription factors: versatile regulators of stem and progenitor cell fate. Cell Stem Cell. 2013;12(1):15–30. doi:10.1016/j.stem.2012.12.007.PubMedCentralPubMedCrossRef

Lei Y, Jaradat JM, Owosho A, Adebiyi KE, Lybrand KS, Neville BW et al. Evaluation of SOX2 as a potential marker for ameloblastic carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol. 2014;117(5):608–16e1. doi:10.1016/j.oooo.2014.01.017.

10.

Heikinheimo K, Voutilainen R, Happonen RP, Miettinen PJ. EGF receptor and its ligands, EGF and TGF-alpha, in developing and neoplastic human odontogenic tissues. Int J Dev Biol. 1993;37(3):387–96.PubMed

11.

Kurppa KJ, Caton J, Morgan PR, Ristimaki A, Ruhin B, Kellokoski J, et al. High frequency of BRAF V600E mutations in ameloblastoma. J Pathol. 2014;232(5):492–8. doi:10.1002/path.4317.PubMedCrossRef

12.

Sweeney RT, McClary AC, Myers B, Biscocho J, Neahring L, Kwei KA, et al. Identification of recurrent SMO and BRAF mutations in ameloblastomas. Nat Genet. 2014;46(7):722–5.PubMedCrossRef

13.

Bilodeau EA, Hoschar AP, Barnes EL, Hunt JL, Seethala RR. Clear cell carcinoma and clear cell odontogenic carcinoma: a comparative clinicopathologic and immunohistochemical study. Head Neck Pathol. 2011;5(2):101–7. doi:10.1007/s12105-011-0244-4.PubMedCentralPubMedCrossRef

14.

Li TJ, Yu SF, Gao Y, Wang EB. Clear cell odontogenic carcinoma: a clinicopathologic and immunocytochemical study of 5 cases. Arch Pathol Lab Med. 2001;125(12):1566–71. doi:10.1043/0003-9985(2001)125<1566:CCOC>2.0.CO;2.PubMed

15.

Weinreb I. Hyalinizing clear cell carcinoma of salivary gland: a review and update. Head Neck Pathol. 2013;7(Suppl 1):S20–9. doi:10.1007/s12105-013-0466-8.PubMedCrossRef

16.

Bilodeau EA, Weinreb I, Antonescu CR, Zhang L, Dacic S, Muller S, et al. Clear cell odontogenic carcinomas show EWSR1 rearrangements: a novel finding and a biological link to salivary clear cell carcinomas. Am J Surg Pathol. 2013;37(7):1001–5. doi:10.1097/PAS.0b013e31828a6727.PubMedCrossRef

17.

Yancoskie AE, Sreekantaiah C, Jacob J, Rosenberg A, Edelman M, Antonescu CR, et al. EWSR1 and ATF1 rearrangements in clear cell odontogenic carcinoma: presentation of a case. Oral Surg Oral Med Oral Pathol Oral Radiol. 2014. doi:10.1016/j.oooo.2014.02.004.PubMed

18.

Gardner D, Kessler H, Morency R, Schaffner D. The glandular odontogenic cyst: an apparent entity. J Oral Pathol. 1988;17:359–66.PubMedCrossRef

19.

Padayachee A, Van Wyk CW. Two cystic lesions with features of both the botryoid odontogenic cyst and the central mucoepidermoid tumour: sialo-odontogenic cyst? J Oral Pathol. 1987;16(10):499–504.PubMedCrossRef

20.

Fowler CB, Brannon RB, Kessler HP, Castle JT, Kahn MA. Glandular odontogenic cyst: analysis of 46 cases with special emphasis on microscopic criteria for diagnosis. Head Neck Pathol. 2011;5(4):364–75. doi:10.1007/s12105-011-0298-3.PubMedCentralPubMedCrossRef

21.

Kaplan I, Anavi Y, Hirshberg A. Glandular odontogenic cyst: a challenge in diagnosis and treatment. Oral Dis. 2008;14(7):575–81. doi:10.1111/j.1601-0825.2007.01428.x.PubMedCrossRef

22.

Kaplan I, Gal G, Anavi Y, Manor R, Calderon S. Glandular odontogenic cyst: treatment and recurrence. J Oral Maxillofac Surg. 2005;63(4):435–41.PubMedCrossRef

23.

Kaplan I, Anavi Y, Manor R, Sulkes J, Calderon S. The use of molecular markers as an aid in the diagnosis of glandular odontogenic cyst. Oral Oncol. 2005;41(9):895–902. doi:10.1016/j.oraloncology.2005.04.015.PubMedCrossRef

24.

Bouquot JE, Gnepp DR, Dardick I, Hietanen JH. Intraosseous salivary tissue: jawbone examples of choristomas, hamartomas, embryonic rests, and inflammatory entrapment: another histogenetic source for intraosseous adenocarcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2000;90(2):205–17.PubMedCrossRef

25.

Brookstone MS, Huvos AG. Central salivary gland tumors of the maxilla and mandible: a clinicopathologic study of 11 cases with an analysis of the literature. J Oral Maxillofac Surg. 1992;50(3):229–36.PubMedCrossRef

26.

Eversole L, Sabes W, Rovin S. Aggressive growth and neoplastic potential of odontogenic cysts. Cancer. 1975;35:270–82.PubMedCrossRef

27.

Garcia J, Barnes E, Cieply K, Dacic S, Jordan R, Seethala R. Utility of MAML2 rearrangement detection using fluorescent in situ hybridization to distinguish glandular odontogenic cyst from central mucoepidermoid carcinoma. Mod Pathol. 2001;24:277A–8A.

28.

Bishop J, Yonescu R, Batista D, Westra W. Glandular odontogenic cysts consistently lack the MAML2 Rearrangements that are frequently found in central mucoepidermoid carcinomas. Modern Pathol. 2014;27:315A–6A.

29.

Argyris PP, Wehrs RN, Garcia JJ, Koutlas IG. Fluorescence in situ hybridization identifies mastermind-like 2 (MAML2) rearrangement in odontogenic cysts with mucous prosoplasia. A Pilot Study. Histopathology. 2014. doi:10.1111/his.12526.PubMed

30.

Brannon RB. The odontogenic keratocyst. A clinicopathologic study of 312 cases. Part I. Clinical features. Oral Surg Oral Med Oral Pathol. 1976;42(1):54–72.PubMedCrossRef

31.

Morgan TA, Burton CC, Qian F. A retrospective review of treatment of the odontogenic keratocyst. J Oral Maxillofac Surg. 2005;63(5):635–9. doi:10.1016/j.joms.2004.07.026.PubMedCrossRef

32.

Evans D, Farndon, PA. Nevoid basal cell carcinoma syndrome. Internet: University of Washington, Seattle 1993–2014.

33.

Gorlin RJ. Nevoid basal cell carcinoma syndrome. Dermatol Clin. 1995;13(1):113–25.PubMed

34.

Hahn H, Wicking C, Zaphiropoulous PG, Gailani MR, Shanley S, Chidambaram A, et al. Mutations of the human homolog of Drosophila patched in the nevoid basal cell carcinoma syndrome. Cell. 1996;85(6):841–51.PubMedCrossRef

35.

Riddle RD, Johnson RL, Laufer E, Tabin C. Sonic hedgehog mediates the polarizing activity of the ZPA. Cell. 1993;75(7):1401–16.PubMedCrossRef

36.

Bellusci S, Furuta Y, Rush MG, Henderson R, Winnier G, Hogan BL. Involvement of Sonic hedgehog (Shh) in mouse embryonic lung growth and morphogenesis. Development. 1997;124(1):53–63.PubMed

37.

Cobourne MT, Hardcastle Z, Sharpe PT. Sonic hedgehog regulates epithelial proliferation and cell survival in the developing tooth germ. J Dent Res. 2001;80(11):1974–9.PubMedCrossRef

38.

Levanat S, Pavelic B, Crnic I, Oreskovic S, Manojlovic S. Involvement of PTCH gene in various noninflammatory cysts. J Mol Med (Berl). 2000;78(3):140–6.PubMedCrossRef

39.

Peacock ZS, Cox D, Schmidt BL. Involvement of PTCH1 mutations in the calcifying epithelial odontogenic tumor. Oral Oncol. 2010;46(5):387–92. doi:10.1016/j.oraloncology.2010.02.023.PubMedCrossRef

40.

Farias LC, Gomes CC, Brito JA, Galvao CF, Diniz MG, de Castro WH, et al. Loss of heterozygosity of the PTCH gene in ameloblastoma. Hum Pathol. 2012;43(8):1229–33. doi:10.1016/j.humpath.2011.08.026.PubMedCrossRef

41.

Stone DM, Hynes M, Armanini M, Swanson TA, Gu Q, Johnson RL, et al. The tumour-suppressor gene patched encodes a candidate receptor for Sonic hedgehog. Nature. 1996;384(6605):129–34. doi:10.1038/384129a0.PubMedCrossRef

42.

Wicking C, Smyth I, Bale A. The hedgehog signalling pathway in tumorigenesis and development. Oncogene. 1999;18(55):7844–51. doi:10.1038/sj.onc.1203282.PubMedCrossRef

43.

Vered M, Peleg O, Taicher S, Buchner A. The immunoprofile of odontogenic keratocyst (keratocystic odontogenic tumor) that includes expression of PTCH, SMO, GLI-1 and bcl-2 is similar to ameloblastoma but different from odontogenic cysts. J Oral Pathol Med. 2009;38(7):597–604. doi:10.1111/j.1600-0714.2009.00778.x.PubMedCrossRef

44.

Levanat S, Gorlin RJ, Fallet S, Johnson DR, Fantasia JE, Bale AE. A two-hit model for developmental defects in Gorlin syndrome. Nat Genet. 1996;12(1):85–7. doi:10.1038/ng0196-85.PubMedCrossRef

45.

Agaram NP, Collins BM, Barnes L, Lomago D, Aldeeb D, Swalsky P, et al. Molecular analysis to demonstrate that odontogenic keratocysts are neoplastic. Arch Pathol Lab Med. 2004;128(3):313–7. doi:10.1043/1543-2165(2004)128<313:MATDTO>2.0.CO;2.PubMed

46.

Moreira PR, Guimaraes MM, Guimaraes AL, Diniz MG, Gomes CC, Brito JA, et al. Methylation of P16, P21, P27, RB1 and P53 genes in odontogenic keratocysts. J Oral Pathol Med. 2009;38(1):99–103. doi:10.1111/j.1600-0714.2008.00718.x.PubMedCrossRef

47.

Zedan W, Robinson PA, Markham AF, High AS. Expression of the Sonic Hedgehog receptor “PATCHED” in basal cell carcinomas and odontogenic keratocysts. J Pathol. 2001;194(4):473–7.PubMedCrossRef

48.

Barreto DC, Bale AE, De Marco L, Gomez RS. Immunolocalization of PTCH protein in odontogenic cysts and tumors. J Dent Res. 2002;81(11):757–60.PubMedCrossRef

49.

Iwasaki JK, Srivastava D, Moy RL, Lin HJ, Kouba DJ. The molecular genetics underlying basal cell carcinoma pathogenesis and links to targeted therapeutics. J Am Acad Dermatol. 2012;66(5):e167–78. doi:10.1016/j.jaad.2010.06.054.PubMedCrossRef

50.

Dreier J, Felderer L, Barysch M, Rozati S, Dummer R. Basal cell carcinoma: a paradigm for targeted therapies. Expert Opin Pharmacother. 2013;14(10):1307–18. doi:10.1517/14656566.2013.798644.PubMedCrossRef

51.

Gorlin RJ, Pindborg JJ, Odont, Clausen FP, Vickers RA. The calcifying odontogenic cyst—a possible analogue of the cutaneous calcifying epithelioma of Malherbe. An analysis of fifteen cases. Oral Surg Oral Med Oral Pathol. 1962;15:1235–43.PubMedCrossRef

52.

Reichart PA, Philipsen H. Calcifying ghost cell odontogenic cysts/tumors. Odontogenic Tumors and Allied Lesions. London: Quintessence; 2004. p. 155–78.

53.

Philipsen HP, Reichart PA, Praetorius F. Mixed odontogenic tumours and odontomas. Considerations on interrelationship. Review of the literature and presentation of 134 new cases of odontomas. Oral Oncol. 1997;33(2):86–99.PubMedCrossRef

54.

Cho YA, Yoon HJ, Hong SP, Lee JI, Hong SD. Multiple calcifying hyperplastic dental follicles: comparison with hyperplastic dental follicles. J Oral Pathol Med. 2011;40(3):243–9. doi:10.1111/j.1600-0714.2010.00968.x.PubMedCrossRef

55.

Sedano HO, Pindborg JJ. Ghost cell epithelium in odontomas. J Oral Pathol. 1975;4(1):27–30.PubMedCrossRef

56.

Hirshberg A, Kaplan I, Buchner A. Calcifying odontogenic cyst associated with odontoma: a possible separate entity (odontocalcifying odontogenic cyst). J Oral Maxillofac Surg. 1994;52(6):555–8.PubMedCrossRef

57.

Polakis P. Wnt signaling and cancer. Genes Dev. 2000;14(15):1837–51.PubMed

58.

Miyake T, Tanaka Y, Kato K, Tanaka M, Sato Y, Ijiri R, et al. Gene mutation analysis and immunohistochemical study of beta-catenin in odontogenic tumors. Pathol Int. 2006;56(12):732–7. doi:10.1111/j.1440-1827.2006.02039.x.PubMedCrossRef

59.

Sekine S, Sato S, Takata T, Fukuda Y, Ishida T, Kishino M, et al. Beta-catenin mutations are frequent in calcifying odontogenic cysts, but rare in ameloblastomas. Am J Pathol. 2003;163(5):1707–12.PubMedCentralPubMedCrossRef

60.

Tanaka A, Okamoto M, Yoshizawa D, Ito S, Alva PG, Ide F, et al. Presence of ghost cells and the Wnt signaling pathway in odontomas. J Oral Pathol Med. 2007;36(7):400–4. doi:10.1111/j.1600-0714.2007.00550.x.PubMedCrossRef

61.

Wijn MA, Keller JJ, Giardiello FM, Brand HS. Oral and maxillofacial manifestations of familial adenomatous polyposis. Oral Dis. 2007;13(4):360–5. doi:10.1111/j.1601-0825.2006.01293.x.PubMedCrossRef

62.

Hegde M, Ferber M, Mao R, Samowitz W, Ganguly A. Working Group of the American College of Medical G et al. ACMG technical standards and guidelines for genetic testing for inherited colorectal cancer (Lynch syndrome, familial adenomatous polyposis, and MYH-associated polyposis). Genet Med. 2014;16(1):101–16. doi:10.1038/gim.2013.166.

63.

Regezi JA, Kerr DA, Courtney RM. Odontogenic tumors: analysis of 706 cases. J Oral Surg. 1978;36(10):771–8.PubMed

64.

Simon EN, Merkx MA, Vuhahula E, Ngassapa D, Stoelinga PJ. Odontogenic myxoma: a clinicopathological study of 33 cases. Int J Oral Maxillofac Surg. 2004;33(4):333–7. doi:10.1016/j.ijom.2003.12.004.PubMedCrossRef

65.

Peltola J, Magnusson B, Happonen RP, Borrman H. Odontogenic myxoma—a radiographic study of 21 tumours. Br J Oral Maxillofac Surg. 1994;32(5):298–302.PubMedCrossRef

66.

Bast BT, Pogrel MA, Regezi JA. The expression of apoptotic proteins and matrix metalloproteinases in odontogenic myxomas. J Oral Maxillofac Surg. 2003;61(12):1463–6.PubMedCrossRef

67.

Zoccali C, Teori G, Prencipe U, Erba F. Mazabraud’s syndrome: a new case and review of the literature. Int Orthop. 2009;33(3):605–10. doi:10.1007/s00264-007-0483-x.PubMedCentralPubMedCrossRef

68.

Weinstein LS, Shenker A, Gejman PV, Merino MJ, Friedman E, Spiegel AM. Activating mutations of the stimulatory G protein in the McCune–Albright syndrome. N Engl J Med. 1991;325(24):1688–95. doi:10.1056/NEJM199112123252403.PubMedCrossRef

69.

Delaney D, Diss TC, Presneau N, Hing S, Berisha F, Idowu BD, et al. GNAS1 mutations occur more commonly than previously thought in intramuscular myxoma. Mod Pathol. 2009;22(5):718–24. doi:10.1038/modpathol.2009.32.PubMedCrossRef

70.

Friedrich RE, Scheuer HA, Assaf AT, Grob T, Zustin J. Odontogenic myxomas are not associated with GNAS1 mutations. Anticancer Res. 2012;32(5):2169–72.PubMed

71.

Carney JA, Gordon H, Carpenter PC, Shenoy BV, Go VL. The complex of myxomas, spotty pigmentation, and endocrine overactivity. Medicine (Baltimore). 1985;64(4):270–83.PubMedCrossRef

72.

Stratakis CA. Mutations of the gene encoding the protein kinase A type I-alpha regulatory subunit (PRKAR1A) in patients with the “complex of spotty skin pigmentation, myxomas, endocrine overactivity, and schwannomas” (Carney complex). Ann N Y Acad Sci. 2002;968:3–21.PubMedCrossRef

73.

Perdigao PF, Stergiopoulos SG, De Marco L, Matyakhina L, Boikos SA, Gomez RS, et al. Molecular and immunohistochemical investigation of protein kinase a regulatory subunit type 1A (PRKAR1A) in odontogenic myxomas. Genes Chromosomes Cancer. 2005;44(2):204–11. doi:10.1002/gcc.20232.PubMedCrossRef

74.

Bossis I, Voutetakis A, Bei T, Sandrini F, Griffin KJ, Stratakis CA. Protein kinase A and its role in human neoplasia: the Carney complex paradigm. Endocr Relat Cancer. 2004;11(2):265–80.PubMedCrossRef

Title: Molecular and Genetic Aspects of Odontogenic Lesions
Authors: Elizabeth A. Bilodeau
Joanne L. Prasad
Faizan Alawi
Raja R. Seethala
Publication date: 01-12-2014
Publisher: Springer US
Published in: Head and Neck Pathology / Issue 4/2014
Electronic ISSN: 1936-0568
DOI: https://doi.org/10.1007/s12105-014-0588-7

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Molecular and Genetic Aspects of Odontogenic Lesions

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2014

Malignant Odontogenic Tumors: An Update on Selected Tumors

Metastatic Tumors to the Jaws and Mouth

Fibro-Osseous Lesions of the Craniofacial Skeleton: An Update

Recent Developments in Metabolic Bone Diseases: a Gnathic Perspective

Bone- and Cartilage-Forming Tumors and Ewing Sarcoma: An Update with a Gnathic Emphasis

Osteochemonecrosis: An Overview